CD160 and B-cell chronic lymphocytic leukemia: Having previously demonstrated that the CD160FCA can reliably detect residual CLL to a threshold of 10-4 (0.01%) (19), in this study, the CD160-ROR1FCA was validated against the original CD160FCA and ERIC methodologies down to an accuracy of 10-5 (0.001%).